Announcement on Obtaining Government Subsidy
Filed with SSE · · 1 page · Chinese
Chengdu Olymvax Biopharmaceuticals Inc. on 6ix
Later from Chengdu Olymvax Biopharmaceuticals
- Announcement on Voluntary Disclosure of Initiation of Phase I Clinical Trial for Trivalent and Tetravalent Influenza Vaccine (Split Virus, MDCK Cells) and Completion of First Subject Enrollment
- Announcement on Preliminary Earnings Estimate for 2024
- Announcement on Change of Sponsor Institution and Sponsor Representative
- Announcement on Provision for Asset Impairment in 2024
- Announcement on Convening 2024 Annual Performance and Cash Dividend Briefing
Follow Chengdu Olymvax Biopharmaceuticals into a list and get an email when it puts out news.
Follow Chengdu Olymvax Biopharmaceuticals